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In a randomized, double-blinded, placebo-controlled trial, we previously showed that intra-dermal administration of
a killed Mycobacterium vaccae suspension to school-aged children with atopic dermatitis ameliorates their dis-
ease. We wished to test the hypothesis that M. vaccae may also prevent the development of eczema. As it was not
possible to do this in children, we studied the NC/Nga eczema mouse model. Thirty NC/Nga mice were randomized
into a blinded, placebo-controlled trial where they received either 0.1 or 0.01 mg of M. vaccae (SRP299) or placebo
given subcutaneously at 1 and 8 wk of age. Clinical eczema scores, as well as scratching frequency using a digital
videotape system were assessed during the 26-wk study. Digital scratch scores correlated with clinical severity
(p¼ 0.001). Although there were no significant differences in age of onset or severity of the rash between the three
study arms, mice injected with 0.1 mg but not 0.01 mg of SPR299 had significantly lower peak scratch frequencies
than controls (Hazard ratio 0.2; 95% conﬁdence interval 0.1–0.7; p¼ 0.01). We conclude that in this NC/Nga mouse
model, SRP299 did have a beneﬁcial effect in reducing pruritis, a major clinical symptom of eczema, although it
does not prevent the rash from developing.
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We have previously shown in a randomized, double-blind-
ed, placebo-controlled trial that intra-dermal administration
of a suspension of killed Mycobacterium vaccae to school-
aged children with moderately severe atopic dermatitis
ameliorates their disease (Arkwright and David, 2001).
Based on this observation, we wished to test the hypoth-
esis that M. vaccae might also prevent the development of
atopic dermatitis. Administration of M. vaccae to atopy-
prone newborn infants was not possible and we therefore
studied the efficacy of a killed M. vaccae suspension
(SRP299) in preventing the development of eczema in the
NC/Nga mouse model. As pruritis and thus scratching is
a central clinical feature of eczema, we not only assessed
the clinical severity of the eczematous rash but also the
scratching behavior of the mice using a recently validated
digital videotape system (Orito et al, 2004).
Dermatitis of the NC mouse has many similarities to that
of human atopic dermatitis and develops spontaneously
around the time of weaning in conventionally housed mice,
but not in those housed in pathogen-free environments
(Vestergaard et al, 2000). Dry, pruritic, lichenified skin le-
sions develop on the face, ears, neck, and back. Histolog-
ically, the skin lesions are characterized by hyperkeratosis,
acanthosis, and parakeratosis, with a dermal infiltration of
lymphocytes, eosinophils, mast cells, and macrophages.
Serum IgE levels are high and IFN-g and IL-4 are expressed
by mast cells and lymphocytes. Th1 cytokines exacerbate
the dermatitis (Matsumoto et al, 2001). Th2 lymphocytes are
not essential as STAT6 NC knockout mice develop derma-
titis of similar severity to controls (Yagi et al, 2002). Steroid
and tacrolimus ointment ameliorates the dermatitis when
applied topically (Hiroi et al, 1998) and subcutaneous ad-
ministration of transforming growth factor-b1 (TGF-b1) also
ameliorates the disease (Sumiyoshi et al, 2002). SRP299
has previously been shown to suppress airway eosinophilia
when injected subcutaneously into BALB/c mice and this
effect can be blocked using anti-TGF-b antibodies (Zuany-
Amorin et al, 2002). If subcutaneous injection of SRP299
were able to increase the activity of TGF-b in the NC mouse,
then it might also ameliorate the dermatitis in this model.
Results and Discussion
General characteristics of study population Ten mice
were randomized to each of three different treatment arms.
All mice had developed eczema by 26 wk. There were no
significant differences in the distribution of males and fe-
males between the groups (placebo group: seven males,
0.01 mg SRP299 group: five males; 0.1 mg SRP299 group:
four males) (w2 test; p¼0.4). In this study cohort, male mice
had a significantly more severe clinical course in terms of an
earlier age of onset (males 10 (8–13) wk vs females 18
(11–23) wk; p¼ 0.01) and a higher peak clinical severity
Abbreviations: CI, confidence interval; TGF-b1, transforming
growth factor-b1
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score (males 14 (10–17) wk vs females 6 (4–15) wk; p¼0.01),
although peak scratch frequency was similar (males 38
(25–67) wk vs females 30 (22–62) wk; p¼0.5). There was
also a significant trend for mice, which developed eczema
at an early age (age of onset of eczema in weeks) to have a
higher peak clinical severity score (Spearman’s r¼0.58;
po0.001). No adverse effects of the treatment were noted
and none of the mice developed a local reaction. In the
overall study population, at any point in time, there was a
significant correlation between clinical eczema severity and
scratch frequency as assessed using the SCLABA digital
videotape system (Spearman’s r¼ 0.41; po0.001) (Fig 1).
The correlation between the peak clinical and peak scratch
scores was, however, not significant (Spearman’s r¼0.14;
p¼0.2).
Effect of M. vaccae (SRP299) on eczema in NC/Nga
mice No significant differences between the three treat-
ment groups as to the age of onset of dermatitis (Kruskal–
Wallis test; p¼0.5) or peak clinical eczema severity (p¼ 0.2)
were observed (Figs 2 and 3A). The ages at which the mice
developed peak clinical severity and peak scratch score
were also similar between the treatment groups (p¼ 0.8).
But the median peak scratch frequency (inter-quartile range)
was significantly lower in mice injected with 0.1 mg (30
(24–33); p¼0.002 (Mann–Whitney U test)) but not 0.01 mg
of SRP299 (16 (10–76); p¼0.2) when compared with the
control group (53 (43–77)) (Fig 3B). Multi-variant analysis
showed that controlling for gender did not effect the above
trends (Table I).
Discussion This study demonstrated that although admin-
istration of M. vaccae did not delay the onset or reduce the
severity of the eczematous rash, it was associated with a
significant reduction in peak scratching frequency in NC/
Nga mice given the higher (0.1 mg), but not lower (0.01 mg)
dose of M. vaccae when compared with the control. Using
the 95% confidence intervals displayed in Table I, we can
be confident that the 0.1 mg dose of SRP299 will lead to a
minimum of a 30% reduction in peak scratch frequency,
whereas it will not decrease peak clinical eczema score by
more than 10% or delay the onset of the eczema by more
than 10%. A larger degree of variability is present in the 0.01
Figure 1
Scatterplot showing the correlation between clinical eczema score
and scratch frequency during an 18-min observation period in NC/
Nga mice. Simultaneous measurements of the two scores were made
on individual mice between 8 and 26 wk of age. N¼ 120 measure-
ments. Calculated linear regression line is shown.
Figure2
Comparative effects of placebo, SRP299 (0.01 mg dose), and
SRP299 (0.1 mg dose) on the age of onset (weeks) of eczema
(clinical eczema scores42) in NC/Nga mice. Bars represent median
value.
Figure3
Comparative effects of placebo, SRP299 (0.01 mg dose), and
SRP299 (0.1 mg dose) on the peak severity of eczema in NC/Nga
mice. (A) Peak clinical eczema score, (B) peak scratch frequency. Bars
represent median value. po0.05 (Kruskal–Wallis H test).
EFFECT OF M. VACCAE IN NC/NGA MICE 141124 : 1 JANUARY 2005
mg dose SRP299 results and thus further larger studies are
required to support these data.
How does one explain the discrepancy between the ob-
served improvement in pruritis/scratching behavior and the
rash in these animals? Pruritis is the primary clinical problem
in eczema (Stander and Steinhoff, 2002). It is the itch-pro-
voked scratching that leads to secondary damage of the
skin and thus the rash. The severity of the rash is not only
determined by the underlying inflammatory eczematous
process but is also influenced by confounding factors, par-
ticularly the degree of secondary bacterial infection. Meas-
urement of scratching behavior is therefore likely to be a
more direct and sensitive measure of the primary eczema-
tous process than the rash. This may be particularly relevant
to the study of laboratory animals because their housing,
level of hygiene, and cleanliness are more likely to promote
secondary bacterial infection of damaged skin, thus con-
founding the clinical picture even more so than with children.
We have previously shown that administration of M. vac-
cae to children with moderately severe eczema is associ-
ated with a significant improvement in school-aged children
(Arkwright and David, 2001), but is no more effective than
control in preschool children (Arkwright and David, 2003). If
M. vaccae were also less efficacious in young mice, then
assessment of a more direct and sensitive measure of the
eczematous process, such as scratching behavior, might
show a significant improvement, whereas no difference in
the rash per se would be observed.
There will always be doubts as to the validity of animal
models in the study of human disease. The clinical course,
histology, and immunology suggest that the NC/Nga mouse
is a useful model to study at least some aspects of human
atopic dermatitis. The results of this study provide some
evidence for a beneficial effect of M. vaccae even in young
animals. Testing this compound in young infants is the next
step in order to determine whether this compound has a
useful therapeutic place in this group of patients. The study
of this NC/Nga mouse model has highlighted the fact that
pruritis and thus scratching behavior need to be considered
when assessing clinical eczema severity. Better measures
of assessing this aspect of the disease in children are re-
quired if our understanding of the clinical aspects of this
condition are to advance.
Materials and Methods
Mice Thirty NC/Nga mice housed in a non-specific pathogen-free
environment (231C  21C, 60%  10%, humidity, laboratory chow,
and water ad libitum) were randomized into three equal groups of
10 mice to receive a subcutaneous injection of (1) 0.1 mg (108 CFU)
of M. vaccae (SRP299) (a gift from SR Pharma plc, London, UK), (2)
0.01 mg (107 CFU) of SRP299, or (3) buffer alone in a volume of
0.1 mL at 1 wk and again at 8 wk of age. P. D. A. randomized the
animals using a web-based random number generation program
(www.graphpad.com/quickcalcs/randomize1.cfm). C. F., who was
blinded to the treatment arm to which the mice had been ran-
domized, made all clinical measurements as detailed below. An-
imal experiments complied with the standards in the guidelines of
the University Animal Care and Use Committee of Tokyo University
of Agriculture and Technology. All mice completed the study and
were used in the analysis.
Assessment of eczema Clinical eczema scores were assessed
using the method previously described (Matsuda et al, 1997).
Briefly, the total clinical severity score was defined as the sum of
the individual scores graded as 0 (none), 1 (mild), 2 (moderate), and
3 (severe) for each of five signs and symptoms (itch, erythema/
hemorrhage, edema, excoriation/erosion, and scaling/dryness).
Scores were determined weekly from 5 until 26 wk of age.
Scratching frequency was assessed at 6 weekly intervals between
8 and 26 wk. Briefly, the nape of the neck and hind limbs were
marked with different colors and each mouse was placed in a
transparent acrylic observation cage. Scratching frequency was
recorded on a videotape for 18 min using a digital video camera
(GR-DV700, JVC, Tokyo, Japan). Data were analyzed using the
SCLABA system (Noveltec, Kobe, Japan) as previously described
and validated in our laboratory (Orito et al, 2004). The primary
outcome measures of the study were (1) age of onset of clinical
eczema score 42, (2) peak clinical eczema score, and (3) peak
scratch frequency score.
Statistical analysis As data in our study were not normally
distributed (defined as mean/SE for skewness and kurtosis o2),
results are quoted as median and inter-quartile range. The Mann–
Whitney U test, Kruskal–Wallis test, and Spearman’s correlation
were used to examine trends in these non-normally distributed
data. w2 analysis was used for binary data. Multi-variant analysis
was performed using Cox regression. All statistics are quoted as
results of two-tailed tests. The software package used was the
SPSS 10.1 statistical package (Chicago, Illinois).
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Table I. Multi-variant analysis showing hazard ratio and 95%
conﬁdence interval (CI) for effects of ‘‘treatment with SRP299’’
and ‘‘gender’’ on the age of onset of eczema (weeks), peak
clinical eczema severity, and peak scratch frequency
Hazard ratio
(95% CI) p-value
Age of eczema onset
0.01 mg SRP299a 0.9 (0.4–2.1) 0.7
0.1 mg SRP299a 0.4 (0.2–1.1) 0.1
Genderb 5.7 (2.1–15.4) 0.001
Peak clinical eczema severity
0.01 mg SRP299a 0.7 (0.3–1.9) 0.5
0.1 mg SRP299a 2.7 (0.9–7.6) 0.1
Genderb 0.3 (0.1–0.7) 0.01
Peak scratch frequency
0.01 mg SRP299a 0.7 (0.3–1.9) 0.5
0.1 mg SRP299a 0.2 (0.1–0.7) 0.01
Genderb 0.8 (0.4–1.8) 0.6
aCox regression: compared with placebo group.
bCox regression: females compared to males.
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